Trial reportThe oncologist2025
Pembrolizumab in recurrent or metastatic medullary thyroid cancer.
Trial report in The oncologist, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT03072160 (Phase II Trial of Pembrolizumab in Recurrent or Metastatic Medullary Thyroid Cancer), which is not on this map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Phase II Trial of Pembrolizumab in Recurrent or Metastatic Medullary Thyroid Cancer
Who cites it
1 citing paper in PubMed.
- Oral Toxicities Associated with Immune Checkpoint Inhibitors: Meta-Analyses of Clinical Trials.Journal of immunotherapy and precision oncology · 2024Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
backgroundIt has been hypothesized that sequencing antigen-directed immunotherapy with immune checkpoint inhibitors could prime a tumor for immune response to immune checkpoint inhibitors.
methodsThis study (NCT03072160) was designed to evaluate two cohorts of patients with medullary thyroid cancer, a cancer that is not known to have therapeutic responses to immune checkpoint inhibitors. One cohort included patients with previous immunotherapy (GI-6207, an experimental therapeutic cancer targeting carcinoembryonic antigen), and a second cohort included patients with no previous history of GI-6207. All patients were treated with standard of care dosing of pembrolizumab, 200 mg every 3 weeks for up to 2 years. Patients were followed with imaging every 3 months. Peripheral blood mononuclear cells (PBMCs) were evaluated at 3 months for immune responses.
results17 patients were enrolled on this study. Among the 13 patients with previous immunotherapy (GI-6207), the median age was 52.4 years. Among the 4 patients with no previous immunotherapy the median age was 58.8 years. No patients in either cohort had evidence of therapeutic response. No patients had confirmed 50% declines in either serum carcinoembryonic antigen or calcitonin. No radiographic responses were observed. There was no evidence of immune impact of pembrolizumab in analysis of PBMCs. Given the lack of responses in the previous immunotherapy cohort, the study was closed early. No new safety signals were observed.
conclusionsThis study did not support the hypothesis that sequencing immunotherapy with an immune checkpoint inhibitor could enhance the clinical activity of the immune checkpoint, which has not demonstrated independent activity in that disease previously.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.